Document Actions
Patient Groups Split On PFS In Front Line Breast Cancer
From The Cancer Letter, Feb. 22, 2008:
Sometime before Feb. 23, FDA will announce its decision on the Genentech drug Avastin. Disputes over Avastin have caused rifts within patient advocacy groups and among drug developers. Opponents argue that acceptance of PFS for this indication would lower the bar for drug approval. Proponents counter that a highly statistically significant delay in progression of disease is a tangible benefit.Click "The Cancer Letter Archive" at left to download this story.
_____
tags:
Friday, February 22, 2008
in
drug development
| Permalink |
Comments (0)
trackback URL: http://www.cancerletter.com/tcl-blog/copy36_of_whats-going-on-with-nih/sbtrackback
Forgot your password?